CIK 0001125345
- Non-accelerated filer
- Smaller reporting company
MACROGENICS INC
Sign in to watch- Ticker
- MGNX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 301-251-5172
- Business address
- 9704 MEDICAL CENTER DRIVE, Rockville, MD, 20850
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-04 | Risser Eric Blasius Chief Operating Officer | Exercise or conversion · Employee stock option (right to buy) | −500 | 0 | ||
| 2022-02-22 | Spitznagel Thomas Sr VP, Technical Ops | Grant or award · Employee stock option (right to buy) | +140,000 | 140,000 | ||
| 2022-02-22 | Risser Eric Blasius Chief Operating Officer | Grant or award · Employee stock option (right to buy) | +170,000 | 170,000 | ||
| 2022-02-22 | Peters Jeffrey Stuart Senior VP and General Counsel | Grant or award · Employee stock option (right to buy) | +70,000 | 70,000 | ||
| 2022-02-22 | Peters Jeffrey Stuart Senior VP and General Counsel | Grant or award · Restricted Stock Unit | +35,000 | 35,000 | ||
| 2022-02-22 | Koenig Scott President and CEO | Grant or award · Employee stock option (right to buy) | +480,000 | 480,000 | ||
| 2022-02-22 | Karrels James SVP, CFO and Secretary | Grant or award · Employee stock option (right to buy) | +140,000 | 140,000 | ||
| 2022-02-22 | Eck Stephen L. Chief Medical Officer | Grant or award · Employee stock option (right to buy) | +150,000 | 150,000 | ||
| 2022-02-22 | Cilinski Lynn VP, Controller and Treasurer | Grant or award · Employee stock option (right to buy) | +63,400 | 63,400 | ||
| 2022-02-22 | Bonvini Ezio Sr VP, Research & CSO | Grant or award · Employee stock option (right to buy) | +75,000 | 75,000 | ||
| 2022-02-22 | Bonvini Ezio Sr VP, Research & CSO | Grant or award · Restricted Stock Unit | +37,500 | 37,500 | ||
| 2021-11-19 | BIOTECH TARGET N V 10% owner | Purchase | +200,000 | $18.50 | $3.7M | 7,275,564 |
| 2021-11-16 | Bonvini Ezio Sr VP, Research & CSO | Exercise or conversion | +2,540 | $16.00 | $41K | 111,090 |
| 2021-11-16 | Bonvini Ezio Sr VP, Research & CSO | Exercise or conversion · Employee stock option (right to buy) | −2,540 | 0 | ||
| 2021-09-29 | BIOTECH TARGET N V 10% owner | Purchase | +100,000 | $20.47 | $2.0M | 7,075,564 |
| 2021-09-28 | BIOTECH TARGET N V 10% owner | Purchase | +100,000 | $20.64 | $2.1M | 6,975,564 |
| 2021-09-17 | BIOTECH TARGET N V 10% owner | Purchase | +200,000 | $19.93 | $4.0M | 6,875,564 |
| 2021-09-16 | BIOTECH TARGET N V 10% owner | Purchase | +400,000 | $20.94 | $8.4M | 6,675,564 |
| 2021-07-16 | Spitznagel Thomas Sr VP, BPD & Manufacturing | Exercise or conversion | +5,000 | $7.51 | $38K | 5,000 |
| 2021-07-16 | Spitznagel Thomas Sr VP, BPD & Manufacturing | Sale | −5,000 | $25.01 | $125K | 0 |
Page 22 of 26 · 503 trades